171 related articles for article (PubMed ID: 8331683)
21. [The location of components of fibrinolytic system in laryngeal cancer].
Sierko E; Tokajuk P; Zimnoch L; Wojtukiewicz MZ
Pol Merkur Lekarski; 2003 Jul; 15(85):81-5. PubMed ID: 14593967
[TBL] [Abstract][Full Text] [Related]
22. Effects of TGF-beta and TNF-alpha on procoagulant and fibrinolytic pathways of human tracheal epithelial cells.
Idell S; Kumar A; Zwieb C; Holiday D; Koenig KB; Johnson AR
Am J Physiol; 1994 Dec; 267(6 Pt 1):L693-703. PubMed ID: 7810674
[TBL] [Abstract][Full Text] [Related]
23. Aqueous extract from Brownea grandiceps flowers with effect on coagulation and fibrinolytic system.
Pereira B; Brazón J
J Ethnopharmacol; 2015 Feb; 160():6-13. PubMed ID: 25460592
[TBL] [Abstract][Full Text] [Related]
24. Pathways of fibrin turnover of human pleural mesothelial cells in vitro.
Idell S; Zwieb C; Kumar A; Koenig KB; Johnson AR
Am J Respir Cell Mol Biol; 1992 Oct; 7(4):414-26. PubMed ID: 1389210
[TBL] [Abstract][Full Text] [Related]
25. Cells of the human myelomonocytic line RC-2A synthesize tissue factor-like procoagulant and urokinase-type plasminogen activator.
Karhumäki E; Saravo L; Helin H
J Leukoc Biol; 1987 Jul; 42(1):36-42. PubMed ID: 3298513
[TBL] [Abstract][Full Text] [Related]
26. Modulation of procoagulant and fibrinolytic system components of mesothelial cells by inflammatory mediators.
Sitter T; Toet K; Fricke H; Schiffl H; Held E; Kooistra T
Am J Physiol; 1996 Nov; 271(5 Pt 2):R1256-63. PubMed ID: 8945961
[TBL] [Abstract][Full Text] [Related]
27. Fibrinogen deposition without thrombin generation in primary human breast cancer tissue.
Costantini V; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Rousseau SM
Cancer Res; 1991 Jan; 51(1):349-53. PubMed ID: 1670992
[TBL] [Abstract][Full Text] [Related]
28. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator.
Yamamoto K; Loskutoff DJ
J Clin Invest; 1996 Jun; 97(11):2440-51. PubMed ID: 8647936
[TBL] [Abstract][Full Text] [Related]
29. [Intraglomerular coagulation and fibrinolysis in human primary glomerular diseases].
Shibata K; Dohi K; Fujii Y; Ishikawa H
Nihon Jinzo Gakkai Shi; 1991 Aug; 33(8):719-29. PubMed ID: 1770632
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
31. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract][Full Text] [Related]
32. Abnormalities of pathways of fibrin turnover in the human pleural space.
Idell S; Girard W; Koenig KB; McLarty J; Fair DS
Am Rev Respir Dis; 1991 Jul; 144(1):187-94. PubMed ID: 2064128
[TBL] [Abstract][Full Text] [Related]
33. [The study of plasminogen activator in renal cell carcinoma with special remarks on urokinase type plasminogen activator].
Hata M
Nihon Hinyokika Gakkai Zasshi; 1989 Nov; 80(11):1558-65. PubMed ID: 2512407
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
[TBL] [Abstract][Full Text] [Related]
35. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
Schmalfeldt B; Kuhn W; Reuning U; Pache L; Dettmar P; Schmitt M; Jänicke F; Höfler H; Graeff H
Cancer Res; 1995 Sep; 55(18):3958-63. PubMed ID: 7664262
[TBL] [Abstract][Full Text] [Related]
36. Dipyridamole stimulates urokinase production and suppresses procoagulant activity of rabbit alveolar macrophages: a possible mechanism of antithrombotic action.
Hasday JD; Sitrin RG
Blood; 1987 Feb; 69(2):660-7. PubMed ID: 3801675
[TBL] [Abstract][Full Text] [Related]
37. u-PA expression in benign, borderline and malignant ovarian tumors.
Kiziridou AD; Toliou T; Stefanou D; Agnantis N
Anticancer Res; 2002; 22(2A):985-90. PubMed ID: 12014682
[TBL] [Abstract][Full Text] [Related]
38. The expression of plasminogen activator system in a rat model of periodontal wound healing.
Xiao Y; Li H; Bunn C; Bartold PM
J Periodontol; 2001 Jul; 72(7):849-57. PubMed ID: 11495131
[TBL] [Abstract][Full Text] [Related]
39. Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.
Alonso DF; De Lorenzo MS; Tejera AM; Gomez DE
Oncol Rep; 1998; 5(1):209-12. PubMed ID: 9458324
[TBL] [Abstract][Full Text] [Related]
40. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
Sitter T; Toet K; Quax P; Kooistra T
Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
